Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1646420rdf:typepubmed:Citationlld:pubmed
pubmed-article:1646420lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:1646420lifeskim:mentionsumls-concept:C0039663lld:lifeskim
pubmed-article:1646420lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:1646420lifeskim:mentionsumls-concept:C0007370lld:lifeskim
pubmed-article:1646420lifeskim:mentionsumls-concept:C1521797lld:lifeskim
pubmed-article:1646420lifeskim:mentionsumls-concept:C0205099lld:lifeskim
pubmed-article:1646420lifeskim:mentionsumls-concept:C1706089lld:lifeskim
pubmed-article:1646420lifeskim:mentionsumls-concept:C0599668lld:lifeskim
pubmed-article:1646420pubmed:issue1lld:pubmed
pubmed-article:1646420pubmed:dateCreated1991-7-17lld:pubmed
pubmed-article:1646420pubmed:abstractTextIn experiments in which mice were placed with their forepaws over a 4 cm high horizontal bar, delta-9-tetrahydrocannabinol (THC; 10 mg/kg i.p.) delayed descent from the bar. This effect on descent latency was markedly enhanced by physostigmine (0.05 or 0.25 mg/kg s.c.) and oxotremorine (0.04 or 0.08 mg/kg s.c.), administered immediately before THC. These interactions were attenuated by atropine (2.0 mg/kg s.c.) and (-)-scopolamine (1.9 mg/kg s.c.) but not by atropine methyl nitrate (2.11 mg/kg s.c.), which does not readily cross the blood-brain barrier. However, atropine methyl nitrate did prevent salivation induced by oxotremorine in the presence of THC. No synergism was detected between THC and neostigmine (0.047 mg/kg s.c.). Atropine and (-)-scopolamine also decreased the ability of chlordiazepoxide (10 mg/kg s.c.) to enhance the effect of THC on descent latency. The interaction was not antagonized by atropine methyl nitrate or mecamylamine (1.17 or 2.34 mg/kg s.c.). These results point to an involvement of central acetylcholine-releasing pathways in the cataleptic response of mice to THC.lld:pubmed
pubmed-article:1646420pubmed:languageenglld:pubmed
pubmed-article:1646420pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:citationSubsetIMlld:pubmed
pubmed-article:1646420pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1646420pubmed:statusMEDLINElld:pubmed
pubmed-article:1646420pubmed:monthJanlld:pubmed
pubmed-article:1646420pubmed:issn0028-3908lld:pubmed
pubmed-article:1646420pubmed:authorpubmed-author:PertweeR GRGlld:pubmed
pubmed-article:1646420pubmed:authorpubmed-author:RossT MTMlld:pubmed
pubmed-article:1646420pubmed:issnTypePrintlld:pubmed
pubmed-article:1646420pubmed:volume30lld:pubmed
pubmed-article:1646420pubmed:ownerNLMlld:pubmed
pubmed-article:1646420pubmed:authorsCompleteYlld:pubmed
pubmed-article:1646420pubmed:pagination67-71lld:pubmed
pubmed-article:1646420pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:meshHeadingpubmed-meshheading:1646420-...lld:pubmed
pubmed-article:1646420pubmed:year1991lld:pubmed
pubmed-article:1646420pubmed:articleTitleDrugs which stimulate or facilitate central cholinergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice.lld:pubmed
pubmed-article:1646420pubmed:affiliationDivision of Pharmacology, Marischal College, University of Aberdeen, U.K.lld:pubmed
pubmed-article:1646420pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1646420lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1646420lld:pubmed